GSA Capital Partners’s TScan Therapeutics TCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$161K Sell
510,700
-37,387
-7% -$25.8K 0.01% 1640
2026
Q2
$537K Buy
548,087
+169,127
+45% +$180K 0.03% 954
2026
Q1
$383K Buy
378,960
+152,796
+68% +$163K 0.02% 1093
2025
Q4
$226K Buy
+226,164
New +$327K 0.02% 1339
2025
Q2
– Sell
-41,817
Closed -$58K – 2138
2025
Q1
$58K Buy
+41,817
New +$90.4K 0.01% 1540

Other funds holding TCRX

GSA Capital Partners's TCRX Position: Q3 2026 in Review

GSA Capital Partners reduced its TScan Therapeutics (TCRX) stake by 6.8% in Q3 2026, selling an estimated $25.8K and leaving 510,700 shares worth $161K. The position accounts for 0.01% of the portfolio, ranked #1640.

GSA Capital Partners first reported a position in TCRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $537K in Q2 2026. 52 funds tracked by Wall St. Rank hold TCRX as of Q3 2026.

  • GSA Capital Partners held 510,700 shares of TScan Therapeutics worth $161K as of Q3 2026.
  • GSA Capital Partners sold 37,387 TScan Therapeutics shares in Q3 2026, an estimated $25.8K.
  • TScan Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1640 holding.
  • GSA Capital Partners first reported a position in TScan Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • GSA Capital Partners's TScan Therapeutics position peaked at $537K in Q2 2026.
  • 52 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.